The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy
Authors:
- Sarah N. BarnardSBSarah N. Barnard
- Zhibin ChenZCZhibin Chen
- Andres M. KannerAKAndres M. Kanner
- Manisha G. HolmesMHManisha G. Holmes
- Pavel KleinPKPavel Klein
- Bassel W. Abou-KhalilBABassel W. Abou-Khalil
- Barry E. GidalBGBarry E. Gidal
- Jacqueline FrenchJFJacqueline French
- Piero PeruccaPPPiero Perucca
- For The Human Epilepsy ProjectFPFor The Human Epilepsy Project
- 8 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (7) , e209821
Abstract
Systematic screening can help identify antiseizure medication (ASM)-associated adverse events (AEs) that may preclude patients from reaching effective doses or completing adequate trial periods. The Adverse Event Profile (AEP) is a self-completed instrument to identify the frequency of common AEs associated with ASM use. This study aimed to compare the AE profile of commonly used ASMs in adults with newly diagnosed focal epilepsy. The Human Epilepsy Project is a prospective, international, observational study investigating markers of treatment response in newly diagnosed focal epilepsy. Participants were enrolled within 4 months of treatment initiation. Adult participants on levetiracetam, lamotrigine, carbamazepine, or oxcarbazepine monotherapy who completed the AEP and Mini International Neuropsychiatric Interview at enrollment were included. Multivariable generalized linear and penalized logistic regression models assessed differences in total and itemized marginal AEP scores and dichotomized responses ("never/rarely" vs "sometimes/always"). A total of 225 adults initiated on levetiracetam (n = 132, 59%), lamotrigine (n = 55, 24%), carbamazepine (n = 19, 8.4%), or oxcarbazepine (n = 19, 8.4%) were included. There were no significant differences in AEP total scores between ASMs. Patients with depression (adjusted marginal score ratio [aMSR] 1.23, 95% CI 1.09-1.39, p = 0.001) and anxiety (aMSR 1.15, 95% CI 1.04-1.26, p = 0.007) had worse AEP total scores than those without. After adjusting for depression and anxiety, levetiracetam users were >3 times more likely to report feelings of aggression (adjusted odds ratio [aOR] 3.38, 95% CI 1.07-10.7, p = 0.038) and almost half as likely to experience unsteadiness (aOR 0.45, 95% CI 0.21-0.99, p = 0.047) than lamotrigine users. Carbamazepine and oxcarbazepine had the highest rates of discontinuation (42.1%, each), followed by levetiracetam (34.8%) and lamotrigine (16.4%). Levetiracetam users had the highest proportion of discontinuations because of AEs alone (18%), and lamotrigine had the lowest (5%). Systematic screening for AEs in adults with newly diagnosed focal epilepsy on ASM monotherapy showed that those with comorbid psychiatric conditions report greater AEs overall, irrespective of ASM. Levetiracetam was associated with >3-fold risk of psychiatric AEs and half the risk of experiencing unsteadiness than lamotrigine. Levetiracetam had the highest proportion of discontinuations because of AEs alone, while lamotrigine had the lowest.Keywords
This publication has 31 references indexed in Scilit:
- Pediatric adverse reactions to antiseizure medications – An analysis of data from the Italian spontaneous reporting system (2001–2019)Epilepsy & Behavior, 2021
- Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic reviewEpilepsy & Behavior, 2021
- Factors related to the adverse events of antiepileptic drugsEpilepsy & Behavior, 2020
- Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed EpilepsyJAMA Neurology, 2020
- Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event?Epilepsy & Behavior, 2017
- Specific adverse effects of antiepileptic drugs — A true-to-life monotherapy studyEpilepsy & Behavior, 2016
- The adverse event profile of levetiracetam: A meta-analysis on children and adultsSeizure: European Journal of Epilepsy, 2015
- Self-reported aggressiveness during treatment with levetiracetam correlates with depressionEpilepsy & Behavior, 2015
- Gender issues in antiepileptic drug treatmentNeurobiology of Disease, 2014
- Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsyEpilepsy & Behavior, 2009